Nkarta's pipeline updates show steady progress, but no major catalysts have emerged. Read what warrants a cautious outlook on ...

The six-year study focused on cyproheptadine, the active compound in the antihistamine Periactin. Periactin is commonly ...

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in ...

Rhabdomyosarcoma is the most frequent cancer affecting soft tissues in children, and existing therapies often fail to stop relapse or prolong survival. Researchers in Germany and the U.K. have ...

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen’s autologous NK cell ...

Immod Innovations, a leader in specialty nutrition, is proud to announce that its flagship supplement, CellBB (Cell Boost and Balance), has been spotlighted in a feature article by Wellness Magazine ...

Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting oblig ...

Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting ...

Mesenchymal stem cell therapy lessens disability and brain lesions in MS patients, according to a review of published studies ...

A new class of South Korean immunotherapy drugs is raising hopes for a breakthrough in the treatment of a rare blood cancer ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell ...